Baillie Gifford & Co
LCTX icon

Baillie Gifford & Co’s Lineage Cell Therapeutics LCTX Stock Holding History

Baillie Gifford & Co’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-25,583
Closed -$78K – 213
2013
Q3 		$78K Hold
25,583
– – ﹤0.01% 206
2013
Q2 		$82K Buy
+25,583
New +$82K ﹤0.01% 179

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Baillie Gifford & Co's LCTX Position: Q4 2013 in Review

Baillie Gifford & Co sold out of Lineage Cell Therapeutics (LCTX) in Q4 2013, closing a stake of 25,583 shares — an estimated $78K sold.

Baillie Gifford & Co first reported a position in LCTX in Q2 2013 and held it in 2 quarters. The position peaked at $82K in Q2 2013. 58 funds tracked by Wall St. Rank hold LCTX as of Q4 2013.

  • Baillie Gifford & Co reported no remaining Lineage Cell Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Baillie Gifford & Co sold 25,583 Lineage Cell Therapeutics shares in Q4 2013, an estimated $78K.
  • Baillie Gifford & Co first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 2 quarters.
  • Baillie Gifford & Co's Lineage Cell Therapeutics position peaked at $82K in Q2 2013.
  • 58 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2013.

Based on Baillie Gifford & Co's 13F filing for Q4 2013, filed 7 Feb 2014.